Aliskiren/amlodipine/hydrochlorothiazide

Aliskiren/amlodipine/hydrochlorothiazide
Combination of
Aliskiren	Renin inhibitor
Amlodipine	Calcium channel blocker
Hydrochlorothiazide	Diuretic
Clinical data
Trade names	Amturnide
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Amturnide; US FDA: Amturnide;
Routes of; administration	By mouth
ATC code	C09XA54 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
PubChem CID	56841821;
KEGG	D10291 ;
Chemical and physical data
Formula	C57H86Cl2N8O15S2
Molar mass	1258.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl;
	InChI InChI=1S/C30H53N3O6.C20H25ClN2O5.C7H8ClN3O4S2/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);5-8,17,23H,4,9-11,22H2,1-3H3;1-2,10-11H,3H2,(H2,9,12,13)/t22-,23+,24-,25-;;/m0../s1; Key:YJDDFLDXUPNQTO-WMEHTASQSA-N;
	(verify)

Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure.^[1]^[2] It contains aliskiren, amlodipine, and hydrochlorothiazide.^[1] It is taken by mouth.^[1]

It was approved for medical use in the United States in December 2010.^[1]^[3]^[4] Amturnide was withdrawn by Novartis from the US market in 2017.^[5]

References

^ ^a ^b ^c ^d ^e "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. 10 November 2016. Retrieved 6 February 2022.
^ Neutel JM, Smith DH (October 2013). "Hypertension management: rationale for triple therapy based on mechanisms of action". Cardiovascular Therapeutics. 31 (5): 251–8. doi:10.1111/1755-5922.12015. PMID 23121769.
^ Amturnide approval letter. U.S. Food and Drug Administration (FDA).
^
"Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review" (PDF). Food and Drug Administration.
^ Department, the Energy (21 June 2017). "Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications" (PDF). Federal Register. Retrieved 6 February 2022.

External links

"FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)". U.S. Food and Drug Administration (FDA). 29 June 2021.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[Amturnide_FDA_label-1] "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. 10 November 2016. Retrieved 6 February 2022.

[Neutel_2013-2] Neutel JM, Smith DH (October 2013). "Hypertension management: rationale for triple therapy based on mechanisms of action". Cardiovascular Therapeutics. 31 (5): 251–8. doi:10.1111/1755-5922.12015. PMID 23121769.

[3] Amturnide approval letter. U.S. Food and Drug Administration (FDA).

[4] "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020.
Lay summary in: "Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review" (PDF). Food and Drug Administration.

[5] Lay summary in: "Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review" (PDF). Food and Drug Administration.

[5] Department, the Energy (21 June 2017). "Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications" (PDF). Federal Register. Retrieved 6 February 2022.

[1]

[2]

[3]

[4]

[5]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan (+HCT) Losartan (+HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +HCT) Valsartan (+amlodipine, +amlodipine and HCT, +HCT, +nebivolol)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Aliskiren/amlodipine/hydrochlorothiazide

References

External links

Navigation menu

Search